Oncobiologics (OTLK)
(Delayed Data from NSDQ)
$2.00 USD
-0.01 (-0.50%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.01 +0.01 (0.50%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OTLK 2.00 -0.01(-0.50%)
Will OTLK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OTLK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OTLK
New Strong Buy Stocks for July 30th
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
OTLK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for OTLK
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina ...
Outlook Therapeutics announces CEO appointment
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as ...
Outlook Therapeutics appoints Bob Jahr as CEO